Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06790368
Recruiting Observational

Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.

NCT06790368 · tracked via the Priya Life Science Spain tracker
Sponsor
Inmunotek S.L
Phase
Observational
Started
2025-01-01
Last updated
2025-05-01

Condition(s) studied

Allergy, Insect VenomAllergy Insect StingingInsect Sting Allergy

Investigational drug(s) / intervention(s)

VENOX →

VENOX: Treatment with allergy vaccine against Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.

Study summary

Observational clinical follow-up to evaluate the safety of immunotherapy for the treatment of hymenoptera venom allergy in real-life conditions. It includes the evaluation of controlled and spontaneous stings. This study will be conducted in Spain (multicentric), multicentric and data will be collected prospectively.

Eligibility

Sex
ALL
Min age
14 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * The study population consisted of allergic participants indicated for treatment with hymenoptera venom immunotherapy (Apis mellifera or Vespula spp.) according to standard clinical practice. * Participants of both sexes aged 14 years or more. * Participants who have not received immunotherapy with hymenoptera venom in the previous 5 years. * Participants who have agreed to take part in the study and sign the informed consent form. In the case of minors, the patient's parent or guardian must also sign. Exclusion Criteria: * Pregnant or breastfeeding women. * Having received immunotherapy with hymenoptera venom during the 5 years prior to the start of the study. * Participants who do not agree to participate and/or do not sign the informed consent form. * Participants who do not comply with medical indications or do not cooperate with immunotherapy treatment.

Primary outcome measure(s)

  • Incidence of treatment-Emergent adverse reactions (safety and tolerability) in participants diagnosed with allergy to hymenoptera venom (Apis mellifera and/or Vespula spp.). — 12 months
    Evaluation of the severity of reactions in relation to subcutaneous immunotherapy following the indications proposed by the World Allergy Organization (WAO).

Trial sites (3)

FacilityCityRegionStatus
Hospital Universitario Fundación Alcorcón Alcorcón Madrid Recruiting
Hospital Reina Sofía Córdoba Spain Recruiting
Hospital Universitario de Guadalajara Guadalajara Spain Recruiting

More Inmunotek S.L. trials in Spain

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df Recruiting
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Recruiting
Determination of Blomia Tropicalis Allergen Extract in Prick Test Units Starting soon
Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy Recruiting
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Recruiting

Other trials for the same condition

Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06790368 on ClinicalTrials.gov ↗ ← All trials in Spain